Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q1 2019 · 10-Q
Revenue$5.21M$5.21M+26.7% vs Q1 2018 Net Income$6.53K$6.53KN/M vs Q1 2018 EPS Diluted$0.00$0.00N/M vs Q1 2018 Gross Profit$3,625,954+72.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Operating Cash Flow$889,969N/M Free Cash Flowderived$876,121N/M Margins · derivedGross margin69.6%+18.4 pt vs Q1 2018
Operating margin2.5%+7.2 pt vs Q1 2018
Net margin0.1%+4.7 pt vs Q1 2018
ended Mar 31, 2019 · filed May 8, 2019 · 38 d after period end